Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Why an HIV patient advocacy group is suing the Trump administration over a Biden administration legal settlement with Gilead ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

Trump targets 2 big Bay Area drugmakers in 'most favored nation' drug-pricing decree ...